Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance

Core Insights - Basilea Pharmaceutica Ltd has reported strong financial results for the fiscal year 2025, achieving total revenue of CHF 232.4 million, an increase of 11.4% year-on-year, driven by robust sales of its products and a significant rise in royalty income [3][4][12] Financial Performance - Total revenue for 2025 was CHF 232.4 million, up from CHF 208.5 million in 2024, with royalty income increasing by 15.4% to CHF 111.6 million [3][4] - Product revenue decreased to CHF 50.8 million from CHF 57.8 million due to the planned expiration of a product-supply agreement with Pfizer [3][9] - Operating profit for 2025 was CHF 51.5 million, down from CHF 61.2 million in 2024, primarily due to a one-time payment for in-licensing [7][9] - Net profit decreased to CHF 40.2 million from CHF 77.6 million in 2024, influenced by the absence of a one-time tax benefit recorded in the previous year [7][9] Research and Development - Basilea invested CHF 105.9 million in R&D in 2025, a significant increase from CHF 77.1 million in 2024, focusing on ongoing phase 3 studies and new product development [4][5] - The company is advancing its pipeline, including fosmanogepix and ceftibuten-ledaborbactam, with plans to launch these products by 2030 [14][15] Financial Guidance - For FY 2026, Basilea expects a double-digit increase in total revenue and a 20% increase in operating profit, supported by strong sales of Cresemba and Zevtera [12][19] - The company anticipates generating approximately CHF 600 million in cumulative positive cash flows from its current commercial products over the next five years [15][19] Market Position and Strategy - Basilea is well-positioned for growth, with Cresemba leading in the treatment of invasive fungal infections and Zevtera now available in the US [2][20] - The company aims to have four commercial assets by 2030, enhancing its R&D pipeline to drive long-term growth [2][14]